Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Caroline M. Hamm"'
Publikováno v:
Journal of Clinical Oncology. 40:e12511-e12511
e12511 Background: Triple-negative breast cancer (TNBC) has been associated with poorer long-term outcomes compared to other breast cancer subtypes. Due to the lack of targeted therapies, the use of adjuvant chemotherapy is the mainstay of treatment,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31c33e91f0e683a2f7716bfbb9a7eb2c
https://doi.org/10.1200/jco.2022.40.16_suppl.e12511
https://doi.org/10.1200/jco.2022.40.16_suppl.e12511
Autor:
Suzana Kovacevic, Krista Naccarato, Stephen Sundquist, Janet Dancey, Youshaa El-Abed, Caroline M. Hamm
Publikováno v:
Journal of Clinical Oncology. 38:e14024-e14024
e14024 Background: Despite recommendations from premier institutions such as NCCN that all cancer patients should be entered on clinical trials, only 3 – 5 % of adult cancer patients are enrolled on clinical trials in North America. The reason for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e60dd8231a0291a54f74fea24459fb0
https://doi.org/10.1200/jco.2020.38.15_suppl.e14024
https://doi.org/10.1200/jco.2020.38.15_suppl.e14024
Publikováno v:
Medical and Pediatric Oncology. 28:65-68
We report a case of congenital retroperitoneal fibrosarcoma presenting in a 17-day-old male in which surgical tumor debulking was followed by chemotherapy. His clinical course was complicated. Intraoperatively, 80% of the tumor was removed and he exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59d42b0af72a73455de31b567d51e221
https://doi.org/10.1002/(sici)1096-911x(199701)28:1<65::aid-mpo13>3.0.co
https://doi.org/10.1002/(sici)1096-911x(199701)28:1<65::aid-mpo13>3.0.co
Autor:
Jean-François Pouliot, Teresa M. Petrella, Richard Tozer, Andre Galarneau, Bryn Pressnail, Michael Smylie, G. Knight, Caroline M. Hamm, Tina Cheng, Jose Chang, Nancy Gregorio, Sudhashree Rajagopal
Publikováno v:
Journal of Clinical Oncology. 32:e20038-e20038
e20038^ Background: Melanoma incidence increased dramatically in the last decades. Intron A is the only adjuvant therapy shown to significantly increase progression-free and overall survival in hig...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cef1383e9b0a9ac6e80fd53d4c8c1dab
https://doi.org/10.1200/jco.2014.32.15_suppl.e20038
https://doi.org/10.1200/jco.2014.32.15_suppl.e20038